Pharmaceuticals

Abelacimab Significantly Reduces Bleeding

Anthos Therapeutics celebrated its Phase II results showing that its novel Factor XI inhibitor abelacimab significantly reduced bleeding among AFib patients compared to the immensely popular blood thinner rivaroxaban (Xarelto).

  • Abelacimab is an investigational monoclonal antibody that locks the Factor XI blood clotting protein in its inactive state, potentially allowing thrombosis treatment without affecting hemostasis.
  • The drug was originally developed by Novartis, before being acquired by Blackstone Life Sciences (Anthos’ parent company) for $250M in 2019.
  • We haven’t yet confirmed how abelacimab measures up to rivaroxaban for reducing stroke risks, but if it proves non-inferior for stroke prevention it could significantly expand anticoagulant treatment options for older and more frail patients.

The AZALEA-TIMI 71 trial included 1,287 global AFib patients with moderate-to-high stroke risks, following them for a median of 21 months before the trial was halted due to “an overwhelming reduction” in bleeding events.

  • The study had abelacimab patients receive either 90 mg or 150 mg subcutaneously each month, or 20mg of rivaroxaban orally every day. 

Actual data on the abelacimab arm’s reduction in bleeding events won’t come out for several months. However, study authors give plenty of reasons to have high expectations, calling the reductions in major or clinically relevant bleeding events “overwhelming,” “unprecedented,” and “highly significant” versus standard-of-care treatment with rivaroxaban.  

  • Anthos also initiated an extension study evaluating patients who were originally in the rivaroxaban arm and switched to abelacimab after the original trial was halted.

Although abelacimab’s immediate next steps are to release full AZALEA-TIMI 71 results and complete its extension study, most attention will be on an ongoing Phase III study confirming its effectiveness with stroke reduction.

The Takeaway

It’s been a while since we’ve seen the medical community get this excited about trial results that didn’t include actual data, highlighting how much clinical demand exists for anticoagulants that don’t pose significant bleeding risks. Abelacimab still has a lot to prove, but if it matches rivaroxaban on stroke prevention it could be well positioned to meet that demand.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!